Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.

@article{Folkman2006AntiangiogenesisIC,
  title={Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.},
  author={Judah M Folkman},
  journal={Experimental cell research},
  year={2006},
  volume={312 5},
  pages={594-607}
}
The first angiogenesis inhibitors for cancer have now been approved by the F.D.A. in the U.S. and in 28 other countries, including China. The majority of these are monotherapies that block VEGF. However, mutant tumor cells may over time produce redundant angiogenic factors. Therefore, for long-term use in cancer, combinations of angiogenesis inhibitors or broad spectrum angiogenesis inhibitors will be needed. The two most broad spectrum and least toxic angiogenesis inhibitors are Caplostatin… CONTINUE READING
Highly Influential
This paper has highly influenced 15 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 265 extracted citations

Similar Papers

Loading similar papers…